期刊文献+

Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy 被引量:10

Characteristics of non-erosive gastroesophageal reflux disease refractory to proton pump inhibitor therapy
暂未订购
导出
摘要 AIM:To investigate whether potent acid inhibition is effective in non-erosive reflux disease (NERD) refractory to standard rabeprazole (RPZ) treatment. METHODS:We treated 10 Japanese patients with NERD resistant to standard dosages of RPZ:10 mg or 20 mg od,20 mg bid,or 10 mg qid for 14 d. All patients completed a frequency scale for symptoms of gastroesophageal reflux disease questionnaire frequency scale for the symptoms of GERD (FSSG); and underwent 24 h pH monitoring on day 14. RESULTS:With increased dosages and frequency of administration of RPZ,median intragastric pH significantly increased,and FSSG scores significantly decreased. With RPZ 10 mg qid,potent acid inhibition was attained throughout 24 h. However,five subjects were refractory to RPZ 10 mg qid,although the median intragastric pH in these subjects (6.6,range:6.2-7.1) was similar to that in the remaining five responsive subjects (6.5,range:5.3-7.3). With baseline RPZ 10 mg od,FSSG scores in responsive patients improved by > 30%,whereas there was no significant decrease in the resistant group. CONCLUSION:NERD patients whose FSSG score fails to decrease by > 30% after treatment with RPZ 10 mg od for 14 d are refractory to higher dosage. AIM:To investigate whether potent acid inhibition is effective in non-erosive reflux disease (NERD) refractory to standard rabeprazole (RPZ) treatment. METHODS:We treated 10 Japanese patients with NERD resistant to standard dosages of RPZ:10 mg or 20 mg od,20 mg bid,or 10 mg qid for 14 d. All patients completed a frequency scale for symptoms of gastroesophageal reflux disease questionnaire frequency scale for the symptoms of GERD (FSSG); and underwent 24 h pH monitoring on day 14. RESULTS:With increased dosages and frequency of administration of RPZ,median intragastric pH significantly increased,and FSSG scores significantly decreased. With RPZ 10 mg qid,potent acid inhibition was attained throughout 24 h. However,five subjects were refractory to RPZ 10 mg qid,although the median intragastric pH in these subjects (6.6,range:6.2-7.1) was similar to that in the remaining five responsive subjects (6.5,range:5.3-7.3). With baseline RPZ 10 mg od,FSSG scores in responsive patients improved by 30%,whereas there was no significant decrease in the resistant group. CONCLUSION:NERD patients whose FSSG score fails to decrease by 30% after treatment with RPZ 10 mg od for 14 d are refractory to higher dosage.
出处 《World Journal of Gastroenterology》 SCIE CAS CSCD 2011年第14期1858-1865,共8页 世界胃肠病学杂志(英文版)
基金 Supported by a Grant-in-Aid from the Japanese Ministry of Education, Culture, Sports, Science and Technology (22790640)
关键词 Non-erosive reflux disease RABEPRAZOLE CYP2C19 质子泵抑制剂 反流 治疗 食管 糜烂 频率范围 pH监测
  • 相关文献

参考文献2

二级参考文献25

  • 1Fass R.Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease.Am J Gastroenterol 2003; 98(Suppl):S2-S7.
  • 2Damiano A,Siddique R,Xu X,Johanson J,Sloan S.Reductions in symptom distress reported by patients with moderately severe,nonerosive gastroesophageal reflux disease treated with rabevrazole.Dig Dis Sci 2003:44:657-662.
  • 3Holtmann G.Reflux disease:the disorder of the third millennium.Eur J Gastroenterol Hepatol 2001;13:S5-11.
  • 4Ho KY,Kang JY,Seow A.Prevalence of gastrointestinal symptoms in a multiracial Asian population,with particular reference to reflux-type symptoms.Am J Gastroenterol 1998;93:1816-1822.
  • 5Wong WM,Lai KC,Lam KF,Hui WM,Hu WH,Lam CL,Xia HH,Huang JQ,Chan CK, Lam SK,Wong BC.Prevalence,clinical spectrum and health care utilization of gastro-oesophageal reflux disease in a Chinese population:a population-based study.Aliment Pharmacol Ther 2003;18:595-604.
  • 6Martinez SD,Malagon IB,Garewal HS,Cui H,Fass R.Nonerosive reflux disease (NERD)-acid reflux and symptom patterns.Aliment Pharmacol Ther 2003;17:537-545.
  • 7Goh KL,Chang CS,Fock KM,Ke M,Park HJ,Lam SK.Gastrooesophageal reflux disease in Asia.J Gastroenterol Hepatol 2000;15:230-238.
  • 8Fock KM,Talley N,Hunt R,Fass R,Nandurkar S,Lam SK,Goh KL,Sollano J. Report of the Asia-Pacific Consensus on the management of gastroesophageal reflux disease.J Gastroenterol Hepatol 2004; 19:357-367.
  • 9Holtmann G,Bytzer P,Metz M,Loeffler V,Blum AL.A randomized, double-blind,comparative study of standarddose rabeprazole and high-dose omeprazole in in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2002;16:479-485.
  • 10Galmiche JP,Zerbib F,Ducrotte P,Fournet J,Rampal P,Avasthy N, Humphries TJ.Decreasing oesophageal acid exposure patients with GERD:a comparison of rabeprazole and omeprazole.Aliment Pharmacol Ther 2001;15:1343-1350.

共引文献45

同被引文献94

引证文献10

二级引证文献105

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部